• Huihui Shi, Man Zhang, Yajing Su, Jingwen Liu, Jiayuan Guo, Mingxin Liu, and Qiuling Ma.
• Second Clinical College of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China.
• Medicine (Baltimore). 2024 Jun 28; 103 (26): e38541e38541.

IntroductionMultiple myeloma (MM) with extramedullary disease (EMD) is rare in clinical practice, and B cell maturation antigen (BCMA) CAR-T cell therapy is a novel therapy for hematologic malignancies. Very few reports have been published on the effect of CAR-T-cell therapy in MM with EMD. Here, we report a case of MM with extramedullary lesions treated with BCMA CAR-T therapy.Case PresentationA 66-year-old female patient presented to our hospital with an enlarged left maxillary gingiva.DiagnosisDiagnosis of indolent MM stage III (DS staging) and stage III (ISS and R ISS) with extramedullary lesions.InterventionThe patient underwent a clinical trial of humanized anti-BCMA CAR T cell therapy.ResultsSymptoms improved; left gingival hyperplasia and swelling resolved; left buccal mass resolved; and neck and submandibular masses resolved. Pathological examination of the exfoliated masses showed necrotic tissue.ConclusionMM with extramedullary lesions often has limited treatment options, and traditional chemotherapy methods are ineffective; however, BCMA CAR-T cell therapy can significantly improve the symptoms of extramedullary lesions in MM.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

9 keywords...

hide…